vs

Side-by-side financial comparison of Arcutis Biotherapeutics, Inc. (ARQT) and Thermon Group Holdings, Inc. (THR). Click either name above to swap in a different company.

Thermon Group Holdings, Inc. is the larger business by last-quarter revenue ($147.3M vs $129.5M, roughly 1.1× Arcutis Biotherapeutics, Inc.). Arcutis Biotherapeutics, Inc. runs the higher net margin — 13.4% vs 12.4%, a 1.0% gap on every dollar of revenue. On growth, Arcutis Biotherapeutics, Inc. posted the faster year-over-year revenue change (81.5% vs 9.6%).

Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.

Thermon Group Holdings, Inc. is a global provider of engineered thermal management solutions, specializing in heat tracing systems, heating cables, temperature monitoring controls, and associated installation support services. It serves core industrial segments including oil and gas, chemical processing, power generation, and food and beverage, with operating bases across North America, Europe, Asia-Pacific, and Latin America.

ARQT vs THR — Head-to-Head

Bigger by revenue
THR
THR
1.1× larger
THR
$147.3M
$129.5M
ARQT
Growing faster (revenue YoY)
ARQT
ARQT
+71.8% gap
ARQT
81.5%
9.6%
THR
Higher net margin
ARQT
ARQT
1.0% more per $
ARQT
13.4%
12.4%
THR

Income Statement — Q2 FY2026 vs Q3 FY2026

Metric
ARQT
ARQT
THR
THR
Revenue
$129.5M
$147.3M
Net Profit
$17.4M
$18.3M
Gross Margin
91.0%
46.6%
Operating Margin
14.2%
18.1%
Net Margin
13.4%
12.4%
Revenue YoY
81.5%
9.6%
Net Profit YoY
-1.3%
EPS (diluted)
$0.13
$0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARQT
ARQT
THR
THR
Q2 26
$129.5M
Q1 26
$105.4M
Q4 25
$129.5M
$147.3M
Q3 25
$99.2M
$131.7M
Q2 25
$81.5M
$108.9M
Q1 25
$65.8M
Q4 24
$71.4M
Q3 24
$44.8M
Net Profit
ARQT
ARQT
THR
THR
Q2 26
$17.4M
Q1 26
$-11.3M
Q4 25
$17.4M
$18.3M
Q3 25
$7.4M
$15.0M
Q2 25
$-15.9M
$8.6M
Q1 25
$-25.1M
Q4 24
$-10.8M
Q3 24
$-41.5M
Gross Margin
ARQT
ARQT
THR
THR
Q2 26
91.0%
Q1 26
90.7%
Q4 25
91.0%
46.6%
Q3 25
91.2%
46.4%
Q2 25
90.8%
44.1%
Q1 25
86.6%
Q4 24
90.3%
Q3 24
87.7%
Operating Margin
ARQT
ARQT
THR
THR
Q2 26
14.2%
Q1 26
-8.6%
Q4 25
14.2%
18.1%
Q3 25
8.6%
16.4%
Q2 25
-17.9%
10.8%
Q1 25
-37.3%
Q4 24
-10.7%
Q3 24
-87.3%
Net Margin
ARQT
ARQT
THR
THR
Q2 26
13.4%
Q1 26
-10.7%
Q4 25
13.4%
12.4%
Q3 25
7.5%
11.4%
Q2 25
-19.5%
7.9%
Q1 25
-38.1%
Q4 24
-15.1%
Q3 24
-92.8%
EPS (diluted)
ARQT
ARQT
THR
THR
Q2 26
$0.13
Q1 26
$-0.09
Q4 25
$0.14
$0.55
Q3 25
$0.06
$0.45
Q2 25
$-0.13
$0.26
Q1 25
$-0.20
Q4 24
$-0.09
Q3 24
$-0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARQT
ARQT
THR
THR
Cash + ST InvestmentsLiquidity on hand
$42.9M
$46.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$189.5M
$538.7M
Total Assets
$433.0M
$816.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARQT
ARQT
THR
THR
Q2 26
$42.9M
Q1 26
$34.8M
Q4 25
$42.9M
$46.9M
Q3 25
$47.1M
$29.7M
Q2 25
$72.7M
$36.5M
Q1 25
$53.1M
Q4 24
$71.3M
Q3 24
$134.9M
Total Debt
ARQT
ARQT
THR
THR
Q2 26
Q1 26
Q4 25
$109.0M
Q3 25
$108.5M
Q2 25
$108.0M
Q1 25
$107.6M
Q4 24
$107.2M
Q3 24
$204.6M
Stockholders' Equity
ARQT
ARQT
THR
THR
Q2 26
$189.5M
Q1 26
$189.6M
Q4 25
$189.5M
$538.7M
Q3 25
$158.1M
$515.2M
Q2 25
$139.0M
$509.3M
Q1 25
$142.7M
Q4 24
$157.5M
Q3 24
$156.6M
Total Assets
ARQT
ARQT
THR
THR
Q2 26
$433.0M
Q1 26
$460.0M
Q4 25
$433.0M
$816.7M
Q3 25
$371.0M
$778.2M
Q2 25
$352.4M
$765.3M
Q1 25
$344.1M
Q4 24
$348.9M
Q3 24
$437.4M
Debt / Equity
ARQT
ARQT
THR
THR
Q2 26
Q1 26
Q4 25
0.58×
Q3 25
0.69×
Q2 25
0.78×
Q1 25
0.75×
Q4 24
0.68×
Q3 24
1.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARQT
ARQT
THR
THR
Operating Cash FlowLast quarter
$18.0M
Free Cash FlowOCF − Capex
$13.1M
FCF MarginFCF / Revenue
8.9%
Capex IntensityCapex / Revenue
3.3%
Cash ConversionOCF / Net Profit
0.98×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARQT
ARQT
THR
THR
Q2 26
Q1 26
Q4 25
$26.2M
$18.0M
Q3 25
$-1.8M
$7.4M
Q2 25
$324.0K
$10.7M
Q1 25
$-30.4M
Q4 24
$-748.0K
Q3 24
$-34.7M
Free Cash Flow
ARQT
ARQT
THR
THR
Q2 26
Q1 26
Q4 25
$13.1M
Q3 25
$4.4M
Q2 25
$246.0K
$8.3M
Q1 25
$-31.0M
Q4 24
Q3 24
$-34.8M
FCF Margin
ARQT
ARQT
THR
THR
Q2 26
Q1 26
Q4 25
8.9%
Q3 25
3.3%
Q2 25
0.3%
7.6%
Q1 25
-47.1%
Q4 24
Q3 24
-77.8%
Capex Intensity
ARQT
ARQT
THR
THR
Q2 26
Q1 26
Q4 25
0.0%
3.3%
Q3 25
0.0%
2.3%
Q2 25
0.1%
2.2%
Q1 25
0.9%
Q4 24
0.0%
Q3 24
0.3%
Cash Conversion
ARQT
ARQT
THR
THR
Q2 26
Q1 26
Q4 25
1.51×
0.98×
Q3 25
-0.24×
0.50×
Q2 25
1.25×
Q1 25
Q4 24
Q3 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARQT
ARQT

Segment breakdown not available.

THR
THR

Other$73.7M50%
Transferred At Point In Time$56.1M38%
Transferred Over Time$17.5M12%

Related Comparisons